TNFRSF9 and neoplasm: Moreover, the anti-tumoral activities of agonist molecules of CD40/4-1BB pathways have been evidenced in numerous preclinical models, but their clinical application has been hampered by tolerability issues mainly due to the engagement of the target outside the tumor (on-target off-tumor effects).